Literature DB >> 17413322

Characterization of huntingtin pathologic fragments in human Huntington disease, transgenic mice, and cell models.

Gabriele Schilling1, Alexandra Klevytska, Andrew T N Tebbenkamp, Katrin Juenemann, Jillian Cooper, Victoria Gonzales, Hilda Slunt, Michelle Poirer, Christopher A Ross, David R Borchelt.   

Abstract

Huntington disease (HD) is caused by the expansion of a glutamine (Q) repeat near the N terminus of huntingtin (htt), resulting in altered conformation of the mutant protein to produce, most prominently in brain neurons, nuclear and cytoplasmic inclusion pathology. The inclusions and associated diffuse accumulation of mutant htt in nuclei are composed of N-terminal fragments of mutant protein. Here, we used a panel of peptide antibodies to characterize the htt protein pathologies in brain tissues from human HD, and a transgenic mouse model created by expressing the first 171 amino acids of human htt with 82Q (htt-N171-82Q). In tissues from both sources, htt pathologic features in nuclei were detected by antibodies to htt peptides 1-17 and 81-90 but not 115-129 (wild-type huntingtin numbering with 23 repeats). Human HEK 293 cells transfected with expression vectors that encode either the N-terminal 233 amino acids of human htt (htt-N233-82Q) or htt-N171-18Q accumulated smaller N-terminal fragments with antibody-binding characteristics identical to those of pathologic peptides. We conclude that the mutant htt peptides that accumulate in pathologic structures of human HD and httN171-82Q in mice are produced by similar, yet to be defined, proteolytic events in a region of the protein near or within amino acids 90-115.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17413322     DOI: 10.1097/nen.0b013e318040b2c8

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  41 in total

1.  Wild-type HTT modulates the enzymatic activity of the neuronal palmitoyl transferase HIP14.

Authors:  Kun Huang; Shaun S Sanders; Rujun Kang; Jeffrey B Carroll; Liza Sutton; Junmei Wan; Roshni Singaraja; Fiona B Young; Lili Liu; Alaa El-Husseini; Nicholas G Davis; Michael R Hayden
Journal:  Hum Mol Genet       Date:  2011-06-02       Impact factor: 6.150

2.  Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative.

Authors:  Andrew T N Tebbenkamp; Cameron Green; Guilian Xu; Eileen M Denovan-Wright; Aaron C Rising; Susan E Fromholt; Hilda H Brown; Debbie Swing; Ronald J Mandel; Lino Tessarollo; David R Borchelt
Journal:  Hum Mol Genet       Date:  2011-04-22       Impact factor: 6.150

3.  Native mutant huntingtin in human brain: evidence for prevalence of full-length monomer.

Authors:  Ellen Sapp; Antonio Valencia; Xueyi Li; Neil Aronin; Kimberly B Kegel; Jean-Paul Vonsattel; Anne B Young; Nancy Wexler; Marian DiFiglia
Journal:  J Biol Chem       Date:  2012-02-27       Impact factor: 5.157

4.  Transgenic mouse model expressing the caspase 6 fragment of mutant huntingtin.

Authors:  Elaine Waldron-Roby; Tamara Ratovitski; XiaoFang Wang; Mali Jiang; Erin Watkin; Nikolas Arbez; Rona K Graham; Michael R Hayden; Zhipeng Hou; Susumu Mori; Deborah Swing; Mikhail Pletnikov; Wenzhen Duan; Lino Tessarollo; Christopher A Ross
Journal:  J Neurosci       Date:  2012-01-04       Impact factor: 6.167

5.  Vulnerability of newly synthesized proteins to proteostasis stress.

Authors:  Guilian Xu; Amrutha Pattamatta; Ryan Hildago; Michael C Pace; Hilda Brown; David R Borchelt
Journal:  J Cell Sci       Date:  2016-03-29       Impact factor: 5.285

Review 6.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

Review 7.  Animal models for metabolic, neuromuscular and ophthalmological rare diseases.

Authors:  Guillaume Vaquer; Frida Rivière; Maria Mavris; Fabrizia Bignami; Jordi Llinares-Garcia; Kerstin Westermark; Bruno Sepodes
Journal:  Nat Rev Drug Discov       Date:  2013-03-15       Impact factor: 84.694

8.  Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease.

Authors:  Christian Landles; Kirupa Sathasivam; Andreas Weiss; Ben Woodman; Hilary Moffitt; Steve Finkbeiner; Banghua Sun; Juliette Gafni; Lisa M Ellerby; Yvon Trottier; William G Richards; Alex Osmand; Paolo Paganetti; Gillian P Bates
Journal:  J Biol Chem       Date:  2010-01-19       Impact factor: 5.157

9.  Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity.

Authors:  Charity T Aiken; Joan S Steffan; Cortnie M Guerrero; Hasan Khashwji; Tamas Lukacsovich; Danielle Simmons; Judy M Purcell; Kimia Menhaji; Ya-Zhen Zhu; Kim Green; Frank Laferla; Lan Huang; Leslie Michels Thompson; J Lawrence Marsh
Journal:  J Biol Chem       Date:  2009-08-26       Impact factor: 5.157

10.  Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease.

Authors:  Kirupa Sathasivam; Andreas Neueder; Theresa A Gipson; Christian Landles; Agnesska C Benjamin; Marie K Bondulich; Donna L Smith; Richard L M Faull; Raymund A C Roos; David Howland; Peter J Detloff; David E Housman; Gillian P Bates
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.